PKCd is essential for apoptosis, but regulation of the proapoptotic function of this ubiquitous kinase is not well understood. Nuclear translocation of PKCd is necessary and sufficient to induce apoptosis and is mediated via a Cterminal bipartite nuclear localization sequence. However, PKCd is found predominantly in the cytoplasm of nonapoptotic cells, and the apoptotic signal that activates its nuclear translocation is not known. We show that in salivary epithelial cells, phosphorylation at specific tyrosine residues in the N-terminal regulatory domain directs PKCd to the nucleus where it induces apoptosis. Analysis of each tyrosine residue in PKCd by site-directed mutagenesis identified two residues, Y64 and Y155, as essential for nuclear translocation. Suppression of apoptosis correlated with suppressed nuclear localization of the Y-F mutant proteins. Moreover, a phosphomimetic PKCd Y64D/Y155D mutant accumulated in the nucleus in the absence of an apoptotic signal. Forced nuclear accumulation of PKCd-Y64F and Y155F mutant proteins, by attachment of an SV40 nuclear localization sequence, fully reconstituted their ability to induce apoptosis, indicating that tyrosine phosphorylation per se is not required for apoptosis, but for targeting PKCd to the nucleus. We propose that phosphorylation/dephosphorylation of PKCd in the regulatory domain functions as a switch to promote cell survival or cell death.
Introduction
The link between subcellular localization and coordinate activation of specific signaling pathways is an emerging theme in signal transduction. It is clear that the spatial organization of PKCd within a cell is dependent upon both the cell type and the stimulus type (Collazos et al., 2006) . Previous work from our laboratory and others has defined PKCd as a critical regulator of the mitochondrial-dependent apoptotic pathway in vitro and in vivo (Majumder et al., 2000; Humphries et al., 2006) . We have shown that PKCd transiently accumulates in the nucleus in response to etoposide, and that translocation of PKCd to the nucleus is required for caspase cleavage and generation of the proapoptotic PKCd catalytic fragment (dCF) (DeVries-Seimon et al., 2007) . Etoposide-induced nuclear translocation of PKCd requires a C-terminal nuclear localization sequence (NLS), and mutation of this sequence suppresses nuclear accumulation of PKCd as well as apoptosis (DeVries et al., 2002) .
While the structural features required for nuclear import of PKCd have been defined, it remains unclear what triggers nuclear import of PKCd in the apical stages of apoptosis. Phosphorylation on tyrosine residues is an established mechanism that regulates enzyme activation, assembly of protein complexes and protein-protein interactions in cells. PKCd is rapidly phosphorylated on tyrosine residues in response to a wide range of stimuli including agents that induce apoptosis (Steinberg, 2004) . In some cases, specific tyrosine residues in PKCd that are important for apoptosis have been identified by mutagenesis (Konishi et al., 2001; Blass et al., 2002) ; however, the mechanism(s) by which phosphorylation of these tyrosines regulates apoptosis has not been identified. In the current studies we show that etoposide induces rapid tyrosine phosphorylation in the regulatory domain of PKCd, and that phosphorylation at PKCd residues Y64 and Y155 is necessary for the subsequent nuclear accumulation of PKCd. As nuclear accumulation of PKCd is both necessary and sufficient to induce apoptosis (DeVries et al., 2002) , phosphorylation/ dephosphorylation of PKCd on specific tyrosine residues functions as a regulatory switch to promote cell survival or cell death.
Results

PKCd tyrosine phosphorylation
To determine if PKCd is tyrosine phosphorylated in apoptotic cells, endogenous PKCd was immunoprecipitated from etoposide-treated parC5 cells and then subjected to immunoblotting with a pan-phosphotyrosine antibody (4G10). As shown in Figure 1a , etoposide induced an increase in tyrosine phosphorylation of PKCd above that seen in untreated parC5 cells. In the experiment shown here, tyrosine phosphorylation increased within 30 min, was maximal at 60 min and declined to the level seen in untreated cells after 90 min. However, in some experiments tyrosine phosphorylation appeared to be slightly more prolonged (Figure 1b) . Src-like tyrosine kinase family members, as well as the DNA damage responsive tyrosine kinase c-Abl, phosphorylate PKCd Figure 1 Etoposide induces tyrosine phosphorylation of PKCd. (a) ParC5 cells were left untreated (control, c) or treated with 100 mM etoposide for the indicated number of minutes. Endogenous PKCd was immunoprecipitated with an antibody that recognizes an epitope in the N terminus of PKCd, and immunoblots were probed with the anti-pan-phosphotyrosine antibody, 4G10. Immunoblots were stripped and reprobed with a PKCd antibody as indicated. (b) As in (a) except that parC5 cells were left untreated (c) or pretreated with either PP2 or PP3 and then challenged with 100 mM etoposide for the indicated number of hours. (c) Schematic of the approximate position of the Group I (depicted above) and Group II (depicted below) tyrosine residues within PKCd that were mutated to phenylalanine; the position of the caspase cleavage site and the nuclear localization sequence (NLS) are also depicted. (d and e) ParC5 cells were transfected with pGFP, pWTd, Group I pY-Fd mutants (d) or Group II pY-Fd mutants (e) for 48 h. Cells were then fixed, and apoptosis was assayed by TUNEL. Shown below is an immunoblot of transfected cell lysates probed with a GFP antibody to determine relative expression of the GFP-PKCd proteins. In both panels, apoptosis was determined as the percentage of GFP-positive cells that were also TUNEL positive. Asterisks indicate a statistically significant difference (Student's t-test; Po0.05) from WTd. Each experiment was repeated three or more times; a representative experiment is shown. in response to apoptotic agents (Yuan et al., 1998; Yoshida et al., 2002) . In Figure 1b we show that pretreatment with PP2, a dual-specific src-like kinase and c-Abl inhibitor, results in a complete block of both basal and etoposide induced PKCd tyrosine phosphorylation in etoposide-treated parC5 cells, while PP3, the inactive form of PP2, has no effect (Tatton et al., 2003) . These results indicate that an etoposide activated tyrosine kinase(s) mediates rapid but transient tyrosine phosphorylation of PKCd. The kinetics of tyrosine phosphorylation seems to follow the kinetics previously described for nuclear accumulation of PKCd in etoposide-treated cells, suggesting that tyrosine phosphorylation may be the apical event that commits PKCd to the apoptotic pathway (DeVries-Seimon et al., 2007) .
Identification of PKCd tyrosine residues required for apoptosis To understand the functional implications of PKCd tyrosine phosphorylation to apoptosis, we analysed a panel of green fluorescent protein (GFP)-PKCd proteins each of which contained a point mutation in one of the 19 tyrosine residues present in the murine PKCd sequence (Figure 1c) . Tyrosine residues 52, 64, 155, 187, 311, 332, 512, 523 and 537 were selected on the basis of evidence from the literature that phosphorylation at these sites is important for specific functions of PKCd; for the sake of our studies these residues are classified as Group I; the remaining tyrosine residues are classified as Group II residues (tyrosines 12, 120, 236, 238, 446, 451, 469 and 628) . We were able to analyse 17 of the 19 tyrosine residues present in the murine protein by this approach; mutation of the remaining two tyrosines (Y372 and Y565) resulted in generation of unstable proteins. The Y-Fd mutants exhibited in vitro kinase activity similar to the wild-type enzyme, with the exception of Y523Fd, which had no kinase activity, and Y64Fd, which had slightly reduced kinase activity. Analysis of phosphorylation on PKCd priming sites, threonine 505 and serine 643, revealed that both sites were similarly phosphorylated in WTd and all of the Y-Fd mutants analysed (data not shown).
Previous work in our laboratory has shown that overexpression of PKCd in parC5 cells is sufficient to induce apoptosis, thus we utilized this assay to screen for Y-Fd mutant proteins that have an enhanced or abrogated ability to induce apoptosis compared to wildtype PKCd (WTd) (Matassa et al., 2001) . WTd and YFd mutant proteins were expressed in parC5 cells for 48 h, and apoptosis was analysed by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) (Figures 1d and e) . The majority of Y-Fd mutant proteins induced apoptosis to a similar extent as that seen in cells expressing WTd (Figures 1d and e) . However, PKCd-Y64F (Y64Fd) and PKCd-Y155F (Y155Fd) were significantly attenuated in their ability to induce apoptosis. We next generated a double mutant in which PKCd was mutated to phenylalanine at both Y64 and Y155 (DMd). Two independent clones of this mutant (DMd1 and DMd2) were used for the following studies. As seen in Figure 2a , expression of either DMd suppressed apoptosis similar to the Y64Fd and Y155Fd single mutants, suggesting that there are no additive or synergistic affects on apoptosis when PKCd is mutated at both residues.
To determine if Y64Fd or Y155Fd can function as dominant-negative proteins to suppress etoposide-induced apoptosis, we transfected parC5cells with pGFP, pWTd, pY64Fd, pY155Fd or pDMd and challenged these cells with etoposide ( Figure 2b ). Expression of Y64Fd or Y155Fd suppressed apoptosis compared to cells expressing GFP or WTd, suggesting that Y64Fd and Y155Fd can suppress the proapoptotic function of endogenous PKCd in parC5 cells. However, suppression of apoptosis under these conditions is only partial, perhaps due to the fact that the PKCd tyrosine mutants must compete with endogenous PKCd. To address this, we utilized primary cultures of parotid salivary cells derived from PKCdÀ/À mice. Primary parotid cells were isolated from PKCd þ / þ or PKCdÀ/À mice and transduced with AdGFP-PKCd (Ad-WTd), AdGFPPKCd-Y64F (Ad-Y64Fd) or AdGFP-PKCd-DM (AdDMd), treated with etoposide, and apoptosis was assayed by TUNEL. As we have previously shown, and as seen in Figure 2c , PKCdÀ/À cells are defective in apoptosis induced by etoposide. However, expression of PKCd can fully reconstitute the apoptotic response, while expression of Ad-Y64Fd or Ad-DMd does not result in an increase in apoptosis over that observed in PKCdÀ/À cells (Humphries et al., 2006) . These data demonstrate that tyrosine residues at positions Y64 and Y155 are critical for PKCd-induced apoptosis, and suggest that phosphorylation at these residues specifies a proapoptotic function for PKCd. However, the fact that apoptosis is only partially suppressed even in the absence of endogenous PKCd indicates the presence of parallel pathways(s) that also participate in apoptotic signaling.
Phosphorylation at Y64 and Y155 regulates nuclear localization of PKCd Since nuclear accumulation of PKCd is required for apoptosis, we asked whether tyrosine phosphorylation of PKCd is necessary for nuclear localization of PKCd. ParC5 cells were transfected with pWTd, pY52Fd, pY64Fd or pY155Fd, challenged with etoposide and analysed for nuclear localization of the GFP-tagged proteins. Fluorescent microscopy to detect the GFP tag showed perinuclear and cytoplasmic localization for WTd, Y52Fd, Y64Fd and Y155Fd mutants in resting cells ( Figure 3a , top panel). Upon treatment with etoposide, WTd and Y52Fd translocated to the nucleus, while Y64Fd and Y155Fd remained predominantly perinuclear and cytoplasmic (Figure 3a , middle panel). As shown in Figure 3b , treatment with etoposide induced translocation of WTd and the Y52d mutant in 46 and 36% of cells, respectively, while nuclear localization of Y64Fd and Y155Fd was observed in 25 and 14% of cells, respectively. Similar suppression of nuclear localization was observed in cells that were transfected with two independent clones of pDMd (Figure 3b ). Etoposide-induced nuclear localization of the Y64Fd or DMd proteins was also suppressed in PKCdÀ/À cells (Figure 3c ). In contrast, treatment with phorbol 12-myristate 13-acetate (PMA) induced translocation of WTd, Y52Fd, Y64Fd and Y155Fd to the nuclear envelope and the plasma membrane, indicating that tyrosine phosphorylation at these residues is not required for the association of PKCd with cellular membranes (Figure 3a, lower panel) . In fact, all 17 of the 19 tyrosine mutants screened showed normal plasma membrane association in response to PMA (data not shown). These results suggest that tyrosine phosphorylation of PKCd controls nuclear localization through a mechanism distinct from those known to be involved in plasma membrane association.
To determine if tyrosine phosphorylation of PKCd is sufficient to target PKCd to the nucleus we mutated Y64 and Y155 to aspartic acid that mimics the negative charge imparted by phosphorylation. ParC5 cells were transfected with pWTd, pY64F/Y155Fd (DMd1) or pY64D/Y155Dd, and analysed for nuclear localization of the GFP-tagged proteins by fluorescent microscopy. As shown in Figures 4a and b , expression of the Y64D/ Y155Dd mutant results in nuclear targeting of the GFPtagged protein in >50% of transfected cells in the absence of apoptotic stimuli; no further increase in nuclear targeting was observed with the addition of etoposide. This suggests that addition of a negative charge alone at these sites is sufficient to allow nuclear accumulation of PKCd, and that phosphorylation of PKCd at Y64 and Y155 regulates apoptosis by controlling nuclear translocation of PKCd.
Targeting Y64Fd and Y155Fd mutants to the nucleus is sufficient to induce apoptosis If tyrosine phosphorylation at Y64 and Y155 functions only to localize PKCd to the nucleus, we reasoned that nuclear targeting of these mutant proteins by fusion of an SV40-NLS to the N terminus may now allow them to induce apoptosis. These constructs were made in the context of a caspase cleavage mutation (CM) since caspase cleavage of these proteins would result in loss of the SV40-NLS. ParC5 cells transfected with pPKCdCM-SV40 (WTd-SV40), pPKCdCM-Y64F-SV40 (Y64Fd-SV40) or pPKCdCM-Y155F-SV40 (Y155Fd-SV40) exhibited exclusive nuclear localization (data not shown). As previously observed, apoptosis was suppressed in (Figure 4c ). However, targeting Y64Fd-SV40 and Y155Fd-SV40 to the nucleus caused induction of apoptosis similar to their control counterpart, WTd-SV40, and also similar to WTd (Figure 4c ). These results show that forcing Y64Fd and Y155Fd into the nucleus restores these mutants' ability to induce apoptosis and confirms that suppression of nuclear localization accounts for the inability of these mutants to induce apoptosis.
Discussion
PKCd is a key intermediate in the transduction of diverse apoptotic signals; however, the molecular signals that activate the proapoptotic role of this multifunctional kinase are not well understood. Our laboratory and others have shown that nuclear accumulation of PKCd is both necessary and sufficient for apoptosis in response to genotoxins, suggesting that subcellular localization is important for specifying differential functions of this kinase (DeVries et al., 2002) . In previous studies we have shown that PKCd accumulates rapidly, but transiently, in the nucleus in response to etoposide (DeVries-Seimon et al., 2007). Here we show that tyrosine phosphorylation of PKCd occurs with similar kinetics and is the signal that activates proapoptotic signaling of PKCd by inducing nuclear translocation. Our studies define Y64 and Y155 as critical residues for proapoptotic signaling by PKCd and suggest that phosphorylation of PKCd at these residues regulates nuclear translocation and hence cell survival. We analysed 17 of the 19 tyrosine residues in the murine PKCd protein and identified Y64 and Y155 as critical to the proapoptotic function of PKCd. Interestingly, none of the Y-F tyrosine mutants analysed increased apoptosis in our PKCd overexpression assay, suggesting that tyrosine phosphorylation of PKCd does not suppress the proapoptotic function of PKCd in parC5 cells. This is in line with other studies in which activation of tyrosine kinases and tyrosine phosphorylation of PKCd has generally been associated with the promotion of apoptosis (Kajimoto et al., 2001; Konishi et al., 2001; Blass et al., 2002) . A notable exception is glioma cells in which Brodie and colleagues have shown that tyrosine phosphorylation of PKCd can either suppress or promote apoptosis in a stimulus-specific manner. Our findings parallel those of Blass et al. who show that mutation of PKCd Y64 inhibits etoposideinduced apoptosis in glioma cells, however these studies also identified Y187 as critical for the apoptotic response to etoposide, while mutation of Y187 to phenylalanine had no affect on apoptosis either in our overexpression system or in etoposide-treated parC5 cells (data not shown). Our studies also indicate a role for Y155 in nuclear translocation and apoptosis, while, mutation of PKCd Y155 enhanced Sindbis virus (Zrachia et al., 2002) and tumor necrosis factor-related apoptosis-inducing ligand (Okhrimenko et al., 2005) induced apoptosis in glioma cells, suggesting a protective role for this residue. Differences between the Blass et al. report and our current data regarding the role of specific tyrosine residues in PKCd may reflect cellspecific pathways in glioma versus salivary epithelial cells. In this regard, expression of a PKCd Y155 mutant in NIH-3T3 cells induced a higher growth rate and neoplastic characteristics, consistent with the loss of a tumor-suppressing, proapoptotic function (Acs et al., 2000) .
Expression of PKCd mutated at both Y64 and Y155 does not result in additive or synergistic apoptotic defects beyond those seen with the single mutations, suggesting that phosphorylation at these two sites acts in concert to regulate apoptosis. One possibility is that once tyrosine is phosphorylated, PKCd binds with low affinity to a protein containing dual SH2 domains, and that phosphorylation at both Y64 and Y155 is required for this interaction. Alternatively, phosphorylation of PKCd at one of these sites may be required for binding and activation of the tyrosine kinase responsible for phosphorylation of PKCd at the second site. The latter scenario may explain the observation that in addition to the ability of tyrosine kinases to bind to and activate PKCd, under some circumstances these kinases may be activated by PKCd as well (Song et al., 1998; Sun et al., 2000) .
Our findings suggest that the N-terminal regulatory domain of PKCd constrains NLS-dependent import of PKCd into the nucleus in the absence of an apoptotic signal. Phosphorylation of PKCd at Y64 and Y155 in this domain, or removal of the regulatory domain by caspase cleavage, is necessary to enable nuclear accumulation of PKCd. These findings have important ParC5 cells were transfected with pWTd, pDMd1 (Y64F/Y155Fd) or pY64D/Y155Dd for 18 h and then left untreated (white bars) or treated with 50mM etoposide (gray bars) for an additional 6 h. Cells were fixed and nuclear localization of GFPPKCd proteins was analysed by fluorescence microscopy (a) The results are quantified in (b) asterisks indicate a statistically significant difference between untreated cells expressing WTd and Y64D/Y155Dd (Student's t-test; Po0.05). Each experiment was repeated three or more times; a representative experiment is shown. (c) ParC5 cells were transfected with pWTd, pY64Fd, pY155Fd, pWTd-SV40, pY64Fd-SV40 or pY155Fd-SV40 vectors for 48 h and apoptosis was assayed by TUNEL. Expression of the GFP-PKCd proteins was assayed by immunoblot using an anti-GFP antibody. Asterisks indicate a statistically significant difference from WTd (Student's t-test; Po0.05). Each experiment was repeated three or more times; a representative experiment is shown.
implications for our understanding of how the proapoptotic function of PKCd is regulated. As depicted in Figure 5 , we predict that activation of a tyrosine kinase(s) downstream of genotoxic damage (step 1) results in phosphorylation of PKCd on tyrosine (step 2), allowing its nuclear import (step 3). Nuclear localization of endogenous PKCd is transient, possibly due to dephosphorylation of the critical tyrosine sites (DeVries- Seimon et al., 2007) . The fact that the PKCd catalytic fragment lacks the regulatory domain may explain why the dCF localizes to, and is retained in, the nucleus independent of an apoptotic stimulus (DeVries et al., 2002) . Our results suggest that prior to tyrosine phosphorylation at Y64 and Y155, PKCd may be held in a conformation in which the NLS is shielded and unable to interact with molecules required for PKCd nuclear import. As we have previously shown, once in the nucleus PKCd is cleaved by nuclear capsase-3 to generate the proapoptotic dCF (steps 4 and 5) (DeVriesSeimon et al., 2007) . Since dCF is sufficient to activate caspase-3, its presence in the cytoplasm of apoptotic cells may result in amplification of the apoptotic pathway (step 6) (DeVries et al., 2002) . Taken together, our studies suggest the tyrosine phosphorylation of PKCd may integrate diverse cell damage signals prior to caspase activation, and thus serve as a switch between cell survival and cell death.
Materials and methods
Cell culture, preparation of primary salivary cells and reagents The parC5 cell line was cultured as previously described (Anderson et al., 1999) . ParC5 cells were transfected using Fugene 6 Transfection Reagent (Roche Molecular Biochemicals, Indianapolis, IN, USA) according to the manufacturer's protocol. Primary mouse parotid cells were prepared from 5-to 7-week-old PKCdÀ/À mice and PKCd þ / þ littermates as previously described (Limesand et al., 2003; Humphries et al., 2006) . Cells grew to approximately 80% confluency in 5 days and were used at that time for experiments without further passage. PKCdÀ/À mice were a generous gift from Dr Keiichi Nakayama (Kyushu University, Fukuoka, Japan) and maintained in accordance with University of Colorado Denver at Health Sciences Center Laboratory Animal Care guidelines and protocols (Miyamoto et al., 2002) . Etoposide and PMA were purchased from Sigma-Aldrich (St Louis, MO, USA) and dissolved in dimethylsulfoxide (DMSO). The src-like kinase inhibitor PP2, and the inactive control, PP3, were purchased from Calbiochem (San Diego, CA, USA) and dissolved in DMSO. All tissue culture reagents were purchased from Biosource (Rockville, MD, USA) and Mediatech Incorporated Cellgro (Herndon, VA, USA).
Plasmids and construction of GFP-PKCd mutants
Unless stated otherwise, all PKCd constructs were constructed in pEGFP-N1 and encode fusion proteins with GFP attached to the C terminus of PKCd (Clontech, Palo Alto, CA, USA). Generation of the constructs pPKCdWT and pPKCdCM has been previously described (DeVries et al., 2002) . To make the Y-Fd and Y-Dd mutants, tyrosine residues were converted to phenylalanine or aspartic acid in the context of the wildtype PKCd fusion protein GFP-PKCd (WTd) using the mouse PKCd cDNA and the Quick Change Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) per the manufacturer's instructions. The primers used for Y-F site-directed mutagenesis are provided in Supplementary Tables 1 and 2 . pPKCd-Y64F/Y155F (DMd) was generated using pPKCd-Y64F as a template and the primers described in Supplementary Table 1 for pPKCd-Y155F. The pPKCd-Y64D/Y155Dd phosphomimetic was generated in two steps. First, pY64Dd was generated from WTd using the primers: 5 0 -CAACGTTC GACGCCCACATCGATGAAGGCCGTGTTAT-3 0 and 5 0 -ATAACACGGCCTTCATCGATGTGGGCGTCGAACGT TG-3 0 . Second, pY64/Y155Dd was generated using Y64Dd as a template and the primers: 5 0 -CAGGCCAAGATCCACGA CATCAAGAACCACGAGTTTATCGCC-3 0 and 5 0 -GGCG ATAAACTCGTGGTTCTTGATGTCGTGGATCTTGGCC TG-3
0 . An SV40-NLS (amino-acid sequence TPPKKKRKVEDPE) was fused to the N terminus of various GFP-PKCd fusion proteins to target these proteins to the nucleus (Tolcher et al., 2002) . The pPKCdCM construct, which contains a mutated caspase cleavage site, was used as a template for site-directed mutagenesis at residues Y64 and Y155 to create pPKCdCM-Y64F and pPKCdCM-Y155F. This was done to ensure that activated caspases could not cleave these constructs, thus removing the N-terminal SV40-NLS. The SV40-NLS was fused to the N terminus of these constructs by PCR using the primers: 5 0 -GCCTCGAGATGACACCCCCCAAGAAGAA GCGAAAGGTAGAAGATCCCGAAGCACCCTTCCTTC GC-3 0 containing an Xho1 site and 5 0 -GCTCTAGAG TCGCGGCCGCTTTACTTGT-3 0 containing an Xba1 site. Xho1 and Xba1 double restriction digests were inserted into the pEGFP-N1 vector creating the products pPKCdCM-SV40, pPKCdCM-Y64F-SV40 and pPKCdCM-Y155F-SV40. All mutations were confirmed by DNA sequence analysis.
Adenovirus construction and expression in primary salivary cells
The GFP adenovirus has been previously described (Schaack et al., 2001 ). Xho1 and Xba1 double restriction digestion fragments of pPKCdWT, pPKCd-Y64F and pPKCdDM were subcloned into the adenoviral shuttle vector, pXCMV, and recombinant adenoviruses were prepared as described (Graham and Prevec, 1995) . Adenoviruses were titered in HEK293 cells based on GFP expression. Primary parotid cells were transduced with the indicated viruses at a multiplicity of infection (focus-forming units per cell) of 500 in serum-free Dulbecco's modified Eagle's medium for 1 h with occasional shaking. After 1 h of transduction, the medium was aspirated and replaced with normal medium.
Immunoprecipitation and immunoblot analysis Cells were harvested and immunoblots were carried out as previously described (Anderson et al., 1999) . For immunoprecipitation assays, 500 mg of whole-cell lysate protein was incubated overnight at 4 1C with either a monoclonal PKCd antibody (610398, Pharmingen, San Diego, CA, USA) or polyclonal GFP antiserum (ab290, Abcam, Cambridge, UK). The rabbit polyclonal antibody PKCd (sc-213) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse monoclonal antibodies that recognize pan-phosphotyrosine (4G10 (05-321, 1:750 dilution)) or GFP (33-2600, 1:500 dilution) were purchased from Upstate Biotechnology (Lake Placid, NY, USA) and Zymed (San Fransisco, CA, USA), respectively. Super Signal West Pico Luminol/Enhancer Solution (Pierce, Rockford, IL, USA) was used for detection of the proteins.
TUNEL analysis and cell counts TUNEL was performed using In Situ Cell Death Detection TMR Red (Roche Molecular Biochemicals) according to the manufacturer's protocol. For some experiments, cells were transfected or virally transduced with the indicated pPKCd plasmid or adenovirus and stained with 5 mg ml À1 4 0 ,6-diamidino-2-phenylindole dihydrochloride hydrate (DAPI) (Sigma-Aldrich) to visualize the nucleus. Transfected and transduced cells expressing the GFP fusion proteins were visualized with immunofluorescent microscopy and counted using a Â 40 objective. For cells not expressing GFP-PKCd proteins, TUNEL-positive (TMR Red fluor) cells exhibiting chromatin condensation were scored as apoptotic. For cells expressing GFP-PKCd proteins, GFP-positive, TUNEL-positive (TMR Red fluor) cells exhibiting chromatin condensation were scored as apoptotic. More than 400 cells were counted for each variable per experiment.
Fluorescent microscopy
Cells on coverslips were transfected or transduced with pPKCd plasmids or adenoviruses followed by fixation in 2% paraformaldehyde for 15 min. Cells were rinsed with phosphate-buffered saline (PBS) once and stained with 5 mg ml À1 DAPI for an additional 30 min, followed by three 15 min washes in PBS. Cells were analysed for the subcellular localization of GFP-PKCd proteins by fluorescent microscopy. For assessment of nuclear localization, cells were quantified as the total number of GFP-expressing cells per field that had predominantly nuclear localized GFP. More than 300 cells were counted for each variable per experiment.
